染色质
胰腺癌
癌症研究
医学
计算生物学
生物
癌症
计算机科学
内科学
遗传学
DNA
作者
S. Dhara,Sagar Chhangawala,Himanshu Chintalapudi,Gökçe Aşkan,Victoria G. Aveson,Alexandra Massa,Linsey Zhang,David E. Torres,Alvin P. Makohon-Moore,Nicolas Lecomte,Jerry P. Melchor,Jonathan Bermeo,Adrián Cárdenas,Shivam Sinha,Danielle Glassman,Rémy Nicolle,Richard A. Moffitt,Kangkang Yu,S-P. Leppänen,Stephen Laderman
标识
DOI:10.1038/s41467-021-23237-2
摘要
Abstract Unlike other malignancies, therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of molecular markers predicting response. Here we report tumor-cell-intrinsic chromatin accessibility patterns of treatment-naïve surgically resected PDAC tumors that were subsequently treated with (Gem)/Abraxane adjuvant chemotherapy. By ATAC-seq analyses of EpCAM + PDAC malignant epithelial cells sorted from 54 freshly resected human tumors, we show here the discovery of a signature of 1092 chromatin loci displaying differential accessibility between patients with disease free survival (DFS) < 1 year and patients with DFS > 1 year. Analyzing transcription factor (TF) binding motifs within these loci, we identify two TFs (ZKSCAN1 and HNF1b) displaying differential nuclear localization between patients with short vs. long DFS. We further develop a chromatin accessibility microarray methodology termed “ ATAC-array”, an easy-to-use platform obviating the time and cost of next generation sequencing. Applying this methodology to the original ATAC-seq libraries as well as independent libraries generated from patient-derived organoids, we validate ATAC-array technology in both the original ATAC-seq cohort as well as in an independent validation cohort. We conclude that PDAC prognosis can be predicted by ATAC-array, which represents a low-cost, clinically feasible technology for assessing chromatin accessibility profiles.
科研通智能强力驱动
Strongly Powered by AbleSci AI